12/2
12:39 pm
guts
Fractyl Health (NASDAQ:GUTS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
High
Report
Fractyl Health (NASDAQ:GUTS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
12/2
07:00 am
guts
Fractyl Health Reports Positive 6-Month REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure
High
Report
Fractyl Health Reports Positive 6-Month REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure
12/1
07:00 am
guts
Fractyl Health to Participate in the 8th Annual Evercore Healthcare Conference
Low
Report
Fractyl Health to Participate in the 8th Annual Evercore Healthcare Conference
11/21
01:43 pm
guts
Fractyl Health (NASDAQ:GUTS) had its price target raised by analysts at Canaccord Genuity Group Inc. from $6.00 to $8.00. They now have a "buy" rating on the stock.
Low
Report
Fractyl Health (NASDAQ:GUTS) had its price target raised by analysts at Canaccord Genuity Group Inc. from $6.00 to $8.00. They now have a "buy" rating on the stock.
11/12
08:27 pm
guts
Fractyl Health outlines 2026 Revita pivotal data and PMA submission targets as clinical momentum accelerates [Seeking Alpha]
Medium
Report
Fractyl Health outlines 2026 Revita pivotal data and PMA submission targets as clinical momentum accelerates [Seeking Alpha]
11/12
04:32 pm
guts
Fractyl Health Reports Third Quarter 2025 Results; Revita® Clinical Momentum Builds Toward 2026 Pivotal Readout and PMA Filing, Cash Runway Extended into Early 2027 [Yahoo! Finance]
Low
Report
Fractyl Health Reports Third Quarter 2025 Results; Revita® Clinical Momentum Builds Toward 2026 Pivotal Readout and PMA Filing, Cash Runway Extended into Early 2027 [Yahoo! Finance]
11/12
04:05 pm
guts
Fractyl Health Reports Third Quarter 2025 Results; Revita® Clinical Momentum Builds Toward 2026 Pivotal Readout and PMA Filing, Cash Runway Extended into Early 2027
Low
Report
Fractyl Health Reports Third Quarter 2025 Results; Revita® Clinical Momentum Builds Toward 2026 Pivotal Readout and PMA Filing, Cash Runway Extended into Early 2027
11/5
07:00 am
guts
Fractyl Health to Report Third Quarter 2025 Financial Results and Provide Business Updates on November 12, 2025
Low
Report
Fractyl Health to Report Third Quarter 2025 Financial Results and Provide Business Updates on November 12, 2025
10/7
07:00 am
guts
Fractyl Health Announces Potent Preclinical Results from RJVA-002, a Dual GIP/GLP-1 Gene Therapy Candidate for Obesity
Medium
Report
Fractyl Health Announces Potent Preclinical Results from RJVA-002, a Dual GIP/GLP-1 Gene Therapy Candidate for Obesity
10/1
05:15 am
guts
Fractyl Health: Best-Case Results; Financing Dilutes But Removes Overhang [Seeking Alpha]
Medium
Report
Fractyl Health: Best-Case Results; Financing Dilutes But Removes Overhang [Seeking Alpha]
9/28
07:18 am
guts
Fractyl Health (GUTS) Is Up 35.6% After Revita Shows Weight Loss Maintained Post-GLP-1 and $60M Raise [Yahoo! Finance]
High
Report
Fractyl Health (GUTS) Is Up 35.6% After Revita Shows Weight Loss Maintained Post-GLP-1 and $60M Raise [Yahoo! Finance]
9/26
03:16 pm
guts
Fractyl Health (NASDAQ:GUTS) had its price target lowered by analysts at HC Wainwright from $9.00 to $8.00. They now have a "buy" rating on the stock.
Low
Report
Fractyl Health (NASDAQ:GUTS) had its price target lowered by analysts at HC Wainwright from $9.00 to $8.00. They now have a "buy" rating on the stock.
9/26
12:21 pm
guts
Fractyl Health, Inc. (GUTS) REMAIN-1 Midpoint Cohort Three-Month Results Conference Call (Transcript) [Seeking Alpha]
Medium
Report
Fractyl Health, Inc. (GUTS) REMAIN-1 Midpoint Cohort Three-Month Results Conference Call (Transcript) [Seeking Alpha]
9/26
11:09 am
guts
Fractyl Health, Inc. - Special Call [Seeking Alpha]
Medium
Report
Fractyl Health, Inc. - Special Call [Seeking Alpha]
9/26
07:37 am
guts
Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock [Yahoo! Finance]
High
Report
Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock [Yahoo! Finance]
9/26
07:29 am
guts
Fractyl Health Announces Groundbreaking Data from REMAIN-1 Midpoint Cohort Showing Revita® Maintained Weight Loss After GLP-1 Discontinuation [Yahoo! Finance]
High
Report
Fractyl Health Announces Groundbreaking Data from REMAIN-1 Midpoint Cohort Showing Revita® Maintained Weight Loss After GLP-1 Discontinuation [Yahoo! Finance]
9/26
07:05 am
guts
Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock
High
Report
Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock
9/26
07:00 am
guts
Fractyl Health Announces Groundbreaking Data from REMAIN-1 Midpoint Cohort Showing Revita® Maintained Weight Loss After GLP-1 Discontinuation
High
Report
Fractyl Health Announces Groundbreaking Data from REMAIN-1 Midpoint Cohort Showing Revita® Maintained Weight Loss After GLP-1 Discontinuation
9/15
08:06 am
guts
Fractyl Health (NASDAQ:GUTS) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $9.00 price target on the stock.
Medium
Report
Fractyl Health (NASDAQ:GUTS) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $9.00 price target on the stock.
9/5
06:07 pm
guts
Fractyl Health: One-Time Procedure To Lock-In GLP-1 Weight Loss; High Risk, High Reward [Seeking Alpha]
Low
Report
Fractyl Health: One-Time Procedure To Lock-In GLP-1 Weight Loss; High Risk, High Reward [Seeking Alpha]